enfortumab,Pembrolizumab,cisplatin,carboplatin,gemcitabine,erdafitinib,cetrelimab
Astellas,Merck,Seagen,janssen
['urothelial carcinoma', 'cisplatin', 'urothelial', 'enfortumab', 'pembro', ' vedo']
#asco23 presented long- term outcome of enfortumab vedotin + pembrolizumab in first-line (1l) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma
- 40% of patients remain on study after 4 years of follow-up
- high confirmed orr (73.3%)
- 15% cr!! 
GU Oncologist/Clinical Trials/ Experimental Therapeutics @UCD_Cancer @UCDavisHealth via @uofcincy @GoBEARCATS. Tweets= My opinions #RCC #ASCO #immunotherapy